Hi, thank you for letting my husband and I join in…
As I am trying to find information on how to deal with my husband’s sever plaque psoriasis, awful psoriasis flares after docetaxel chemotherapy infusion treatments and high glucose levels/numbers that seem to coincide with these extreme psoriasis flares rising from 140 to 260, although he is Not a diabetic, Has never been told he is a pre-diabetic or diabetic. His mother has diabetes II for most of her life.
I requested germline genetic testing, not really versed on familial and therapeutic implications with PARPi inhibitors. My husbands results show a pathogenic variant in BLM gene (heterozygous), which can be associated with the AR Bloom syndrome.
I also requested genome sequencing done on the biopsy samples
The Tumor genomics were an- Oncomine targeted panel with
Tier 2 variants in p53 and CDH1 and Tier 3 in DNMT3A, HRAS, WT1.
So, our next move is to send out the original 4/15 core samples to Foundation One or another group someone may recommend, I’ll start another controversial thread on that perhaps.
My husband has an active interest is his health, and he is very much in tune and in communication with his physicians. We discuss findings and coshare the results.
He discusses and decides what he wants to do and what he is comfortable doing…Livimg…
He is not interested in anything that a Physician would not suggest or recommend or prescribe.
He has been been seen by three top dermatologist at this point with no suggestion on an oral or injection form of psoriasis therapy that is not a suppressant.
Please read and digest the below with abject caution, it’s not advice as it’s just me sharing some reading material. Please take all with a pinch of salt with a grain of humor.
More Reading on Metformin:
Can metformin affect prostate?
In benign prostate hyperplasia (BPH) xenograft models, metformin inhibits testosterone and attenuates prostate weight and pathological alterations31.
These findings suggest that metformin not only reduced the side effects of ADT but also acted as chemotherapy for ADT through testosterone inhibition.
While the body of evidence to support a role for metformin in prostate cancer therapy is rapidly growing, there is still insufficient data from randomised trials, which are currently still ongoing. However, evidence so far suggests metformin could be a useful adjuvant agent, particularly in patients on ADT.
The study included 567 patients. Patients who used statins or metformin after prostate cancer diagnosis had longer average survival times (9.3 years and 8.1 years, respectively; P=0.001) compared with patients who persistently used or used the medicines prior to cancer diagnosis. Multivariate Cox regression analysis found that patients treated with statins after cancer diagnosis were significantly associated with a lower risk of mortality (aHR =0.24, 95% CI =0.09–0.66) compared to patients who did not use statins during the study period. Patients treated with metformin after cancer diagnosis were significantly associated more with an increased risk of mortality (aHR =6.78, 95% CI =2.45–18.77) compared to patients who did not use metformin during the study period. Sensitivity analysis revealed that the average survival time was similar among different medicine use groups in patients with diabetes. Conclusion: The finding suggests that statins and metformin use after prostate cancer diagnosis may increase survival in patients with hyperlipidemia and radiotherapy.
Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2
ASCO 2019: TAXOMET: Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration Resistant Prostate Cancer Chicago, IL (UroToday.com)
Docetaxel is a standard of care in metastatic castration-resistant prostate cancer (mCRPC), however it is still a palliative treatment with a median overall survival of ~3 years in the first line setting. Thus, innovative strategies to improve survival outcomes are needed. The rationale for using metformin as an anti-cancer drug is such that since it decreases glucose metabolism in the cell, there is an effect on the mitochondria leading to cell cycle arrest.
There is also further rationale for combining docetaxel and metformin:Metformin decreases prostate cancer incidence in a large cohort study (OR 0.84, 95% CI 0.74-0.96)1Metformin improves time to castration-resistance and survival in prostate cancer diabetic patients compared to non-metformin users2Metformin may be an effective chemosensitizer for docetaxel in preclinical models3It is a well-known antidiabetic molecular, low cost, and with minimal side effectsAs such, the addition of metformin could enhance docetaxel efficacy in mCRPC patients. Marc Martin, MD, and his colleagues from France presented results of their trial assessing the efficacy of metformin in combination with docetaxel.
Association between metformin medication, genetic variation and prostate cancer risk
"Jonathan Rauch in “The Constitution of Knowledge: A Defense of Truth” describes:
No one on a patient forum is a doctor, and no one’s advice or personal experience should be taken as definitive. Anecdotes are not evidence. Check everything with your doctor. It is entirely appropriate to ask for source material for advice that goes beyond the standard-of-care, and to discuss those sources with your doctor. But remember that doctors may have little patience for sources that do not come from peer-reviewed journals or are low-level or low-quality evidence